In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Cellectar Biosciences, Inc.. Trade Record

NASDAQ:CLRB Cellectar Biosciences, Inc. stock gains 6.68% Exit Sep 20, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CLRB Sep 12, 2017, priceSeries
About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Trade Information
Trade Type
LONG
ReliabilityScore™
99.60
Entry Date
Sep 12, 2017
Entry Price
16.20
Sell Date
Sep 20, 2017
Sell Price
17.28
Net Gain
6.68%
Hold Time
6 Trading Days